À compter du 1er décembre 2023, l’accès à POEMs et à Essential Evidence Plus ne fera plus partie des avantages offerts aux membres de l’AMC.
Question clinique
Is lanadelumab effective for reducing the attack rate of hereditary angioedema in adolescents and adults?
L’Essentiel
Lanadelumab (Takhzyro) is effective for reducing the attack rate of hereditary angioedema in adolescents and adults (numbers needed to treat = 1.46 - 1.74). 1b
Référence
Plan de l'etude: Randomized controlled trial (double-blinded)
Financement: Industry
Cadre: Outpatient (specialty)
Sommaire
Lanadelumab is a human monoclonal antibody that inhibits the generation of bradykinin, possibly reducing or preventing recurrent attacks of hereditary angioedema. These investigators identified patients, 12 years or older, who met standard diagnostic criteria for hereditary angioedema type I or type II. After a 4-week run-in period, eligible patients (N = 125) who'd had 1 or more confirmed attack during the run-in period randomly received (concealed allocation assignment) subcutaneous lanadelumab at 1 of 3 dose regimens--150 mg every 4 weeks, 300 mg every 4 weeks, or 300 mg every 2 weeks--or matched placebo. Individuals who assessed outcomes remained masked to treatment group assignment. Complete follow-up occurred for 90.4% of participants at 26 weeks. Using intention-to-treat analysis, significantly fewer attacks of hereditary angioedema occurred in all 3 treatment groups than in the placebo group (0.48, 0.53, and 0.26 vs 1.97, respectively). Similarly, a 50% reduction in attack rate from baseline occurred significantly more often in the 3 treatment groups than in the placebo group (89.3%, 100%, and 100% vs 31.7%, respectively; numbers needed to treat = 1.46 - 1.74). Adverse effects were minimal in all treatment groups.
Reviewer
David C. Slawson, MD
Professor and Vice Chair of Family Medicine for Education and Scholarship
Atrium Health
Professor of Family Medicine, UNC Chapel Hill
Charlotte, NC
Commentaires
useless site
useless site